Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule. “Completing this work in the midst of…
LXX.C
Lexaria Bioscience (LXX.C) has received test results for two new DehydraTECH 2.0 cannabidiol (CBD) formulations in its second 2021 applied research and development study program, HYPER-A21-2. “One of our…
Earlier this week, a subsidiary of Lexaria Bioscience (LXX.C) received a R&D license from Health Canada, prompting the question, ‘we have those?’ “You were as surprised as we were,” said…
@presley1000 @ChrisParry nahh he’ll probably take some of the credit lol — dielawn (@Dyro01676) January 9, 2017 There’s an old way of thinking in the marketing game that, if…
Sometimes I can’t even. For a few years now, Lexaria Bioscience (LXX.C) has crept around in the background of the Canadian bongosphere. It had a chequered start, partnering up with…